WO2008012413A3 - Derives de pyrimidinone et leur utilisation comme medicament - Google Patents

Derives de pyrimidinone et leur utilisation comme medicament Download PDF

Info

Publication number
WO2008012413A3
WO2008012413A3 PCT/FR2007/001205 FR2007001205W WO2008012413A3 WO 2008012413 A3 WO2008012413 A3 WO 2008012413A3 FR 2007001205 W FR2007001205 W FR 2007001205W WO 2008012413 A3 WO2008012413 A3 WO 2008012413A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
pyrimidinone derivatives
products
receptors
cannabinoid receptors
Prior art date
Application number
PCT/FR2007/001205
Other languages
English (en)
Other versions
WO2008012413A2 (fr
Inventor
Lydie Poitout
Carole Sackur
Eric Ferrandis
Original Assignee
Sod Conseils Rech Applic
Lydie Poitout
Carole Sackur
Eric Ferrandis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic, Lydie Poitout, Carole Sackur, Eric Ferrandis filed Critical Sod Conseils Rech Applic
Priority to EP07803868A priority Critical patent/EP2054419A2/fr
Priority to US12/375,212 priority patent/US20090325933A1/en
Priority to JP2009521289A priority patent/JP2009544668A/ja
Publication of WO2008012413A2 publication Critical patent/WO2008012413A2/fr
Publication of WO2008012413A3 publication Critical patent/WO2008012413A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente demande a pour objet de nouveaux dérivés pyrimidinone. Ces produits ont une bonne affinité pour certains sous-types de récepteurs de cannabinoides, en particulier les récepteurs CB2. Ils sont particulièrement intéressants pour traiter les états pathologiques et les maladies dans lesquels un ou plusieurs récepteurs des cannabinoides sont impliqués. L'invention concerne également des compositions pharmaceutiques contenant lesdits produits et leur utilisation pour la préparation d'un médicament.
PCT/FR2007/001205 2006-07-27 2007-07-13 Derives de pyrimidinone et leur utilisation comme medicament WO2008012413A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07803868A EP2054419A2 (fr) 2006-07-27 2007-07-13 Derives de pyrimidinone et leur utilisation comme medicament
US12/375,212 US20090325933A1 (en) 2006-07-27 2007-07-13 Pyrimidinone Derivatives and Their Use as a Drug
JP2009521289A JP2009544668A (ja) 2006-07-27 2007-07-13 ピリミジノンの誘導体及びそれらの医薬としての利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0606864A FR2904318B1 (fr) 2006-07-27 2006-07-27 Derives de pyrimidinone et leur utilisation comme medicament
FR0606864 2006-07-27

Publications (2)

Publication Number Publication Date
WO2008012413A2 WO2008012413A2 (fr) 2008-01-31
WO2008012413A3 true WO2008012413A3 (fr) 2008-05-22

Family

ID=37774782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001205 WO2008012413A2 (fr) 2006-07-27 2007-07-13 Derives de pyrimidinone et leur utilisation comme medicament

Country Status (5)

Country Link
US (1) US20090325933A1 (fr)
EP (1) EP2054419A2 (fr)
JP (1) JP2009544668A (fr)
FR (1) FR2904318B1 (fr)
WO (1) WO2008012413A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009001214A2 (fr) * 2007-06-28 2008-12-31 Pfizer Products Inc. Dérivés de thieno[2,3-d]pyrimidin-4(3h)-one, d'isoxazolo[5,4-d]pyrimidin-4(5h)-one et d'isothiazolo[5,4-d]pyrimidin-4(5h)-one utilisés comme antagonistes du récepteur du calcium
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP2020524703A (ja) 2017-06-21 2020-08-20 シャイ・セラピューティクス・エルエルシーＳｈｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｌｃ がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038053A1 (en) * 2003-06-10 2005-02-17 Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy
US20050176742A1 (en) * 2003-06-10 2005-08-11 Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050038053A1 (en) * 2003-06-10 2005-02-17 Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy
US20050176742A1 (en) * 2003-06-10 2005-08-11 Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy

Also Published As

Publication number Publication date
WO2008012413A2 (fr) 2008-01-31
US20090325933A1 (en) 2009-12-31
FR2904318A1 (fr) 2008-02-01
JP2009544668A (ja) 2009-12-17
EP2054419A2 (fr) 2009-05-06
FR2904318B1 (fr) 2011-02-25

Similar Documents

Publication Publication Date Title
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2004075823A8 (fr) Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2008005908A3 (fr) Dérivés de pyridoïmidazole
IL189008A (en) History of 1-Naphthalenyl-3-azabicyclo [0.1.3] hexane
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
WO2008049116A3 (fr) Indoles substitués
GEP20146101B (en) Pyridine and pyrazine derivatives as protein kinase modulators
WO2007090393A3 (fr) Préparation pharmaceutique
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d'opioïdes
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2007149865A3 (fr) Procédés et compositions liés à l'inhibition de la synthèse de la céramide
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2004089951A8 (fr) Derives d’imidazo-pyridine ayant une affinite sur des recepteurs de la melanocortine
WO2009071690A3 (fr) Dérivés d'oxindole à double substitution en positions 5 et 6 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
HK1105197A1 (en) Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists or antagonists of melanocortin receptors
WO2008087366A3 (fr) Derives de 3-phenyl-1-(phenylthienyl)propan-1-one et de 3-phenyl-1-(phenylfuranyl)propan-1-one substitues, preparation et utilisation
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2006097617A3 (fr) Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
EP1975168A4 (fr) Derives de pyrazole carboxamides, compositions pharmaceutiques contenant ces composes et fabrication de ceux-ci
WO2004106322A3 (fr) Polymorphes d'aripiprazole
WO2009084034A3 (fr) Dérivés de chromane utilisés comme modulateurs de trpv3

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2009521289

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007803868

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12375212

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07803868

Country of ref document: EP

Kind code of ref document: A2